Clinical trial NCT02204982: Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Official title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Follicular Lymphoma
Keywords: Phase 3, Follicular Lymphoma, FL, PI3K
Lead sponsor: SecuraBio
Sponsor class: INDUSTRY
First posted: 2014-07-31
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A study to evaluate the safety and efficacy of duvelisib administered in combination with rituximab vs placebo in combination with rituximab in patients with previously treated CD20-positive follicular lymphoma who are not suitable candidates for chemotherapy.

Detailed description: Study IPI-145-08 is an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study designed to evaluate the efficacy and safety of duvelisib in combination with rituximab vs placebo in combination with rituximab in subjects with previously treated CD20-positive follicular lymphoma.

Approximately 400 subjects will receive 25 mg of duvelisib or placebo, orally BID for 28 day continuous cycles, in combination with 375 mg/m2 of Rituximab given once weekly for 4 weeks during Cycle 1 and then once on Day 1 of Cycles 4, 6, 8, and 10. Patients will remain on treatment for up to 27 cycles and may continue treatment if clinical benefit is observed.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of CD20-positive FL:

  * Histology grades 1, 2 or 3a
  * Biopsy-confirmed histopathological diagnosis of FL. Biopsy specimen should be obtained ≤2 years prior to randomization, unless medically contraindicated
* CD20 immunophenotyping performed ≤2 years prior to randomization
* First or subsequent relapse following at least one induction therapy regimen containing rituximab in combination with an anthracycline or rituximab in combination with an alkylating agent
* Patients in first relapse must be chemoresistant or intolerant to chemotherapy
* No response or disease progression ≤ 24 months from start of last previous therapy
* At least 1 measurable disease lesion \>1.5 cm in at least one diameter by CT/CT-PET or magnetic resonance imaging (MRI) in an area of no prior radiation therapy, or in an area that was previously irradiated that has documented progression

Exclusion Criteria:

* Clinical evidence of other indolent forms of lymphoma (e.g., marginal zone lymphoma \[MZL\], small lymphocytic lymphoma \[SLL\])
* Transformation to a more aggressive subtype of lymphoma or grade 3b FL
* Refractory to rituximab: defined as disease progression while receiving or within 6 months of completing either weekly rituximab induction therapy, or rituximab-based chemoimmunotherapy induction
* Intolerance to rituximab or severe allergic or anaphylactic reaction to any humanized or murine monoclonal antibodies
* Prior allogeneic hematopoietic stem cell transplant (HSCT)
* Known Central Nervous System (CNS) lymphoma; subjects with symptoms of CNS disease must have a negative CT scan and negative diagnostic lumbar puncture
* Prior treatment with a PI3K inhibitor or BTK inhibitor
* History of tuberculosis within the preceding two years
* Ongoing systemic bacterial, fungal, or viral infections at randomization (defined as requiring IV antimicrobial, antifungal or antiviral agents)
* Subjects on antimicrobial, antifungal or antiviral prophylaxis are not specifically excluded if all other I/E criteria are met
* Prior, current, or chronic hepatitis B or hepatitis C infection, positive result for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) or hepatitis C virus antibodies (HCV Ab)
* History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months

Primary outcomes:
measure: Progression-Free Survival (PFS)
timeFrame: Until disease progression, for up to 5 years from randomization
Secondary outcomes:
measure: Overall Response Rate (ORR)
timeFrame: Until disease progression, for up to 5 years from randomization
Other outcomes:
Locations:
city: Frankston
country: Australia
state: Victoria
city: Bordeaux
country: France
city: Bologna
country: Italy
city: Terni
country: Italy
city: Gdynia
country: Poland
Study officials:
affiliation: Verastem, Inc.
name: Hagop Youssoufian, MD
role: STUDY_CHAIR
References: